导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.37% | 1892/4773 |
| 近一周 | -1.56% | 525/5462 |
| 近一月 | -1.58% | 978/5421 |
| 近一季 | -4.23% | 1562/5209 |
| 近半年 | -3.36% | 2185/4920 |
| 近一年 | 2.88% | 2031/4366 |
| 近两年 | 49.05% | 1498/2954 |
| 近三年 | 33.02% | 933/2253 |
| 成立以来 | 101.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.40% 2281/4961 |
7.82% 2659/5312 |
- - |
- - |
| 2025 | 17.33% 2386/4813 |
-1.89% 2812/3635 |
5.00% 664/4076 |
13.71% 2970/4524 |
0.16% 2175/4813 |
| 2024 | 20.47% 467/3463 |
4.21% 472/2808 |
-0.75% 828/3014 |
14.56% 1949/3129 |
1.67% 1042/3463 |
| 2023 | -4.92% 703/2656 |
6.61% 666/2280 |
-1.46% 491/2385 |
-2.87% 776/2515 |
-6.82% 1934/2655 |
| 2022 | -14.98% 403/2207 |
-10.85% 434/1919 |
4.49% 1009/2016 |
-10.75% 447/2113 |
2.26% 997/2208 |
| 2021 | 9.30% 458/1822 |
-1.25% 456/1255 |
6.68% 727/1330 |
3.29% 411/1466 |
0.44% 1110/1822 |
| 2020 | 33.53% 456/1250 |
-6.59% 497/1028 |
10.60% 761/1067 |
15.36% 219/1164 |
12.04% 502/1184 |
| 2019 | 27.31% 550/1092 |
25.88% 441/739 |
-2.77% 357/788 |
-1.62% 671/850 |
5.73% 683/918 |
| 2018 | -20.25% 189/834 |
- - |
-7.00% 140/631 |
-2.67% 297/660 |
-9.93% 169/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达上证中盘ETF联接C VS. 长安沪深300非周期A(740101) |